Rosuvastatin + Ezetimibe
Romazic Plus contains two different active substances in one tablet. One of the active substances is rosuvastatin, which belongs to a group of medicines known as statins, and the other active substance is ezetimibe. Romazic Plus is used to lower the level of total cholesterol, "bad" cholesterol (LDL cholesterol), and a type of fat called triglycerides in the blood, and to increase the level of "good" cholesterol (HDL cholesterol). The medicine works by reducing the amount of cholesterol absorbed in the gut and the amount of cholesterol produced by the body.
In most people, high cholesterol levels do not affect their well-being, as they do not cause any symptoms. However, if left untreated, it can lead to the accumulation of fatty deposits in the walls of blood vessels, causing them to narrow.
As a result of the narrowing, it is sometimes possible for the blood vessel to become blocked, cutting off blood flow to the heart or brain, leading to a heart attack or stroke. By lowering cholesterol levels, the risk of heart attack, stroke, or other similar health problems can be reduced.
Romazic Plus is used in patients whose cholesterol levels cannot be controlled by diet alone. While taking this medicine, the patient should continue to follow a cholesterol-lowering diet.
The doctor may prescribe Romazic Plus if the patient is already taking rosuvastatin and ezetimibe in the same doses as in the combination medicine.
Romazic Plus is used in patients:
Romazic Plus does not help with weight loss.
In addition, Romazic Plus 40 mg + 10 mg (the highest dose) should not be taken:
If any of the above situations apply to the patient (or if the patient has doubts), they should consult their doctor.
Before starting to take Romazic Plus, the patient should discuss the following with their doctor:
Additionally:
In rare cases, statins may affect liver function. This can be detected by a simple blood test that checks for increased liver enzyme activity. Therefore, the doctor will recommend regular blood tests while taking Romazic Plus. It is essential for the patient to attend these tests as scheduled.
Severe skin reactions, including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS), have been reported with Romazic Plus. If the patient experiences any of the symptoms described in section 4, they should stop taking Romazic Plus and consult their doctor immediately.
While taking this medicine, the doctor will closely monitor patients with diabetes or at risk of developing diabetes. There is a high risk of developing diabetes if the patient has high blood sugar and fat levels, is overweight, and has high blood pressure.
Romazic Plus should not be used in children and adolescents under 18 years of age.
The patient should inform their doctor or pharmacist about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
The patient should inform their doctor about taking any of the following medicines:
If the patient is to be hospitalized or treated for another condition, they should inform the medical staff that they are taking Romazic Plus.
Romazic Plus 40 mg + 10 mg (the highest dose) should not be taken if the patient regularly consumes large amounts of alcohol.
Romazic Plus should not be taken if the patient is pregnant, trying to become pregnant, or thinks they may be pregnant. If the patient becomes pregnant while taking Romazic Plus, they should stop taking the medicine and inform their doctor. While taking Romazic Plus, women should use effective methods of contraception to avoid becoming pregnant.
Romazic Plus should not be taken during breastfeeding, as it is not known whether the medicine passes into breast milk.
Romazic Plus is unlikely to affect the patient's ability to drive or use machines. However, the patient should be aware that Romazic Plus may cause dizziness. If this occurs, the patient should not drive or use machines.
If the patient has been diagnosed with an intolerance to some sugars, they should consult their doctor before taking Romazic Plus.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is essentially "sodium-free".
This medicine should always be taken exactly as prescribed by the doctor or pharmacist. If the patient has any doubts, they should consult their doctor or pharmacist.
While taking Romazic Plus, the patient should continue to follow a low-cholesterol diet and maintain physical activity.
The recommended daily dose for adults is one tablet of the prescribed strength.
The medicine can be taken at any time of day, with or without food. The tablets should be swallowed whole with water.
Romazic Plus should be taken at the same time every day.
Romazic Plus is not suitable for initiating treatment. If treatment is started or the dose needs to be changed, the patient should take each active substance separately before switching to Romazic Plus at the prescribed strength.
If the doctor prescribes Romazic Plus with another cholesterol-lowering medicine containing colestyramine or any other bile acid sequestrant, Romazic Plus should be taken at least 2 hours before or 4 hours after taking these medicines.
It is essential for the patient to attend regular check-ups with their doctor to monitor their cholesterol levels and ensure they are within the desired range.
In case of overdose, the patient should consult their doctor or the emergency department of the nearest hospital, as medical attention may be necessary.
If a dose is missed, the patient should take the next tablet at the scheduled time. The patient should not take a double dose to make up for the missed dose.
The patient should inform their doctor if they want to stop taking Romazic Plus. After stopping Romazic Plus, cholesterol levels may increase again.
If the patient has any further doubts about taking this medicine, they should consult their doctor or pharmacist.
Like all medicines, Romazic Plus can cause side effects, although not everybody gets them. It is essential for the patient to know what side effects can occur.
Other side effects include:
Other known side effects:
Common side effects (affect less than 1 in 10 people):
Uncommon side effects (affect less than 1 in 100 people):
Rare side effects (affect less than 1 in 1000 people):
Very rare side effects (affect less than 1 in 10,000 people):
Side effects with unknown frequency (cannot be estimated from available data):
The patient should talk to their doctor if they experience muscle weakness in their arms or legs, worsening after periods of activity, double vision, or drooping eyelids, difficulty swallowing, or shortness of breath.
If the patient experiences any side effects, including any side effects not listed in this leaflet, they should inform their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, Tel.: +48 22 49 21 301, Fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, more information can be collected on the safety of this medicine.
The medicine should be stored out of sight and reach of children.
Store in the original packaging to protect from light and moisture. There are no special storage temperature requirements.
Do not use this medicine after the expiry date stated on the carton and blister pack after EXP. The expiry date refers to the last day of the month.
The inscription on the packaging after the abbreviation EXP indicates the expiry date, and after the abbreviation Lot/LOT indicates the batch number.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
The active substances of Romazic Plus are rosuvastatin (in the form of rosuvastatin calcium) and ezetimibe.
Romazic Plus, 5 mg + 10 mg:
Each film-coated tablet contains 5 mg of rosuvastatin (in the form of rosuvastatin calcium) and 10 mg of ezetimibe.
Romazic Plus, 10 mg + 10 mg:
Each film-coated tablet contains 10 mg of rosuvastatin (in the form of rosuvastatin calcium) and 10 mg of ezetimibe.
Romazic Plus, 20 mg + 10 mg:
Each film-coated tablet contains 20 mg of rosuvastatin (in the form of rosuvastatin calcium) and 10 mg of ezetimibe.
Romazic Plus, 40 mg + 10 mg:
Each film-coated tablet contains 40 mg of rosuvastatin (in the form of rosuvastatin calcium) and 10 mg of ezetimibe.
Core of the tablet (the same for all strengths): microcrystalline cellulose, anhydrous colloidal silica, magnesium stearate, povidone K30, sodium croscarmellose, sodium lauryl sulfate, lactose monohydrate, hypromellose.
Coating:
Romazic Plus, 5 mg + 10 mg: hypromellose, titanium dioxide (E 171), macrogol, yellow iron oxide (E 172), red iron oxide (E 172), talc.
Romazic Plus, 10 mg + 10 mg: hypromellose, titanium dioxide (E 171), macrogol, yellow iron oxide (E 172), talc.
Romazic Plus, 20 mg + 10 mg: hypromellose, titanium dioxide (E 171), macrogol, yellow iron oxide (E 172), talc.
Romazic Plus, 40 mg + 10 mg: lactose monohydrate, hypromellose, titanium dioxide (E 171), macrogol.
Romazic Plus, 5 mg + 10 mg: Light yellow, round, biconvex film-coated tablets, approximately 10 mm in diameter, with "EL 5" engraved on one side.
Romazic Plus, 10 mg + 10 mg: Beige, round, biconvex film-coated tablets, approximately 10 mm in diameter, with "EL 4" engraved on one side.
Romazic Plus, 20 mg + 10 mg: Yellow, round, biconvex film-coated tablets, approximately 10 mm in diameter, with "EL 3" engraved on one side.
Romazic Plus, 40 mg + 10 mg: White, round, biconvex film-coated tablets, approximately 10 mm in diameter, with "EL 2" engraved on one side.
The pack contains 28, 30, 56, 60, 84, or 100 film-coated tablets.
Not all pack sizes may be marketed.
Polpharma S.A., ul. Pelplińska 19, 83-200 Starogard Gdański, tel. +48 22 364 61 01
ELPEN Pharmaceutical Co. Inc., Marathonos Ave. 95, 19009 Pikermi Attiki, Greece
RONTIS HELLAS MEDICAL AND PHARMACEUTICAL PRODUCTS S.A., P.O. BOX 3012 Larissa Industrial Area, 41500 Larissa, Greece
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.